Compounds > 2-mercapto-4(3h)-quinazolinone
Page last updated: 2024-12-09

2-mercapto-4(3h)-quinazolinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-mercapto-4(3H)-quinazolinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID683940
CHEMBL ID1232053
SCHEMBL ID894736
MeSH IDM0526912

Synonyms (64)

Synonym
EU-0066865
HMS1578A10
2-thioxo-2,3-dihydroquinazolin-4(1h)-one
STK726938
CHEMBL1232053
inchi=1/c8h6n2os/c11-7-5-3-1-2-4-6(5)9-8(12)10-7/h1-4h,(h2,9,10,11,12
2-mercapto-4(3h)-quinazolinone, 97%
2-sulfanylquinazolin-4-ol
STK409562
2-mercapto(3h)quinazolinone
2-sulfanylquinazolin-4(3h)-one
STK511371
d1v ,
AKOS000284856
AKOS000297154
2-sulfanylidene-1h-quinazolin-4-one
HMS1607A10
13906-09-7
M1089
2-thio-4(3h)-quinazolinone
2-mercapto-4(3h)-quinazolinone
AKOS000120856
AKOS002325460
AKOS003238837
2-mercaptoquinazolin-4(3h)-one
A807474
KUC108902N
ksc-27-034b
2,3-dihydro-2-thioxoquinazolin-4(1h)-one
einecs 237-676-3
FT-0636978
GF-0138
SCHEMBL894736
CS-008/04098013
2-sulfanyl-4(3h)-quinazolinone
2-mercaptoquinazolin-4-one
2-mercapto-4(3 h)-quinazolinone
2-mercaptoquinazoline-4-one
4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline
2-mercapto-3h-quinazolin-4-one
2-sulfanylquinazolin-4(1h)-one
3D1V
2-sulfanyl-3,4-dihydroquinazolin-4-one
mfcd00006885
4(1h)-quinazolinone, 2,3-dihydro-2-thioxo-
2-sulfanylidene-1,2,3,4-tetrahydroquinazolin-4-one
123533-72-2
DTXSID50160880
sr-01000389714
SR-01000389714-1
2-mercapto-4(1h)-quinazolinone
4-hydroxyquinazoline-2(1h)-thione
J-007217
2-thioxoquinazol-4-one
2-sulfanylidene-1,3-dihydroquinazolin-4-one
F0037-9201
2-thioquinazolin-4-one
CS-0063895
STL197914
mfcd00206875
AT22486
Q27459048
2-thioxo-2,3-dihydro-1h-quinazolin-4-one
F13443
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Purine nucleoside phosphorylaseHomo sapiens (human)Kd324.0000324.0000324.0000324.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2008Archives of biochemistry and biophysics, Nov-01, Volume: 479, Issue:1
Structural studies of human purine nucleoside phosphorylase: towards a new specific empirical scoring function.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.79 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310